Use of disease risk scores in pharmacoepidemiologic studies

被引:106
|
作者
Arbogast, Patrick G. [1 ]
Ray, Wayne A. [2 ,3 ]
机构
[1] Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Prevent Med, Nashville, TN 37232 USA
[3] Nashville Vet Adm, Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN 37232 USA
基金
美国医疗保健研究与质量局;
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROPENSITY SCORE; STRATIFICATION; DEATH;
D O I
10.1177/0962280208092347
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Automated databases are increasingly used in pharmacoepidemiologic studies. These databases include records of prescribed medications and encounters with medical care providers from which one can construct very detailed Surrogate measures for both drug exposure and covariates that are potential confounders. Often it is possible to track day-by-day changes in these variables. However, while this information is often critical for study success, its Volume can pose challenges for statistical analysis. One common approach is the use of propensity scores. An alternative approach is to construct a disease risk score. This is analogous to the propensity score in that it calculates a summary measure from the covariates. However, the disease risk score estimates the probability or rate of disease Occurrence conditional oil being unexposed. The association between exposure and disease is then estimated adjusting for the disease risk score in place of the individual covariates. This review describes the use of disease risk scores in phamacoepidemiologic studies, and includes a brief discussion of their history, a more detailed description of their construction and use, a summary of simulation Studies comparing their performance vis-a-vis traditional models, a comparison of their utility with that of propensity scores, and some further topics for future research.
引用
收藏
页码:67 / 80
页数:14
相关论文
共 50 条
  • [21] Use of Polygenic Risk Scores for Coronary Heart Disease in Ancestrally Diverse Populations
    Dikilitas, Ozan
    Schaid, Daniel J.
    Tcheandjieu, Catherine
    Clarke, Shoa L.
    Assimes, Themistocles L.
    Kullo, Iftikhar J.
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (09) : 1169 - 1177
  • [22] Probabilistic Bias Analysis in Pharmacoepidemiologic Studies
    Hunnicutt, Jacob N.
    Ulbricht, Christine M.
    Chrysanthopoulou, Stavroula A.
    Lapane, Kate L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 137 - 138
  • [23] How the Intended Use of Polygenic Risk Scores Guides the Design and Evaluation of Prediction Studies
    Martens, Forike K.
    Janssens, A. Cecile J. W.
    CURRENT EPIDEMIOLOGY REPORTS, 2019, 6 (02) : 184 - 190
  • [24] How the Intended Use of Polygenic Risk Scores Guides the Design and Evaluation of Prediction Studies
    Forike K. Martens
    A. Cecile J.W. Janssens
    Current Epidemiology Reports, 2019, 6 : 184 - 190
  • [25] Polygenic Risk Scores in Human Disease
    Maamari, Dimitri J.
    Abou-Karam, Roukoz
    Fahed, Akl C.
    CLINICAL CHEMISTRY, 2025, 71 (01) : 69 - 76
  • [26] Accounting for Outcome Misclassification in Pharmacoepidemiologic Studies
    Li, Xiaojuan
    Potas, Nihan
    Butler, Anne M.
    Edwards, Jess
    Fin, Jason
    Brookhart, M. Alan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 350 - 351
  • [27] Disease risk scores for skin cancers
    Fontanillas, Pierre
    Alipanahi, Babak
    Furlotte, Nicholas A.
    Johnson, Michaela
    Wilson, Catherine H.
    Pitts, Steven J.
    Gentleman, Robert
    Auton, Adam
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [28] Disease risk scores for skin cancers
    Pierre Fontanillas
    Babak Alipanahi
    Nicholas A. Furlotte
    Michaela Johnson
    Catherine H. Wilson
    Steven J. Pitts
    Robert Gentleman
    Adam Auton
    Nature Communications, 12
  • [29] Trimming on Propensity or Disease Risk Scores to Enhance Validity in the Design of Comparative Effectiveness Studies
    Glynn, Robert J.
    Lunt, Mark
    Sturmer, Til
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 198 - 198
  • [30] The effect of NSAIDs on the risk of coronary heart disease:: fusion of clinical pharmacology and pharmacoepidemiologic data
    Rodríguez, LAG
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (06) : S41 - S44